1. PB2138: VITALIZE TRIAL: A PHASE 2B, OPEN-LABEL, MULTICENTER, RANDOMIZED PARALLEL-GROUP, TWO-STAGE, STUDY OF MAVEROPEPIMUT-S, PEMBROLIZUMAB, WITH OR WITHOUT INTERMITTENT LOW-DOSE CYCLOPHOSPHAMIDE, IN R/R DLBLC. (23rd June 2022) Authors: Lee, E.; Matasar, M.; Conlon, R.; Mody, K.; Fiset, S.; Graff, J. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 2009 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PO-0959 Robust features selection in Apparent Diffusion Coefficient (ADC) maps of cervix cancer patients. (April 2019) Authors: Traverso, A.; Kazmierski, M.; Shi, Z.; Weiss, J.; Fiset, S.; Wee, L.; Dekker, A.; Jaffray, D.; Han, K. Journal: Radiotherapy and oncology Issue: Volume 133(2019)Supplement 1 Page Start: S520 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗